NAD+ (Injectable) vs SS-31 (Elamipretide)

NAD+ (Injectable): Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity. Typical dose 50-200 mg (SubQ); 500-1500 mg (IV) mcg. SS-31 (Elamipretide): Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin. Typical dose 5000-50000 mcg. Both fall under the Longevity category.

Stacking NAD+ (Injectable) with SS-31 (Elamipretide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

NAD+ (Injectable) is typically dosed: Per infusion, weekly to monthly for IV anti-aging clinic protocol; Daily or alternate-day for Subcutaneous wellness; Daily for Intranasal. SS-31 (Elamipretide) is typically dosed: Once daily (SubQ) for Mitochondrial support and longevity.

NAD+ (Injectable): Not FDA approved as a therapeutic. Available via compounding pharmacies for off-label use. NAD+ precursors (NR as Niagen, NMN) sold as dietary supplements. SS-31 (Elamipretide): Not FDA approved. FDA declined approval for Barth syndrome in 2023, requesting additional efficacy data. Multiple clinical trials ongoing for other mitochondrial indications.